
SABCS
19 interviews
San Antonio Breast Cancer Symposium
Interviews and expert commentary from SABCS — study authors and key opinion leaders discuss the findings and their clinical implications.

Hope S. Rugo, MD; SABCS 2025: Selective Estrogen Degrader Giredestrant Brings Clinically Meaningful Improvements in Metastatic Breast Cancer: evERA Breast Cancer Trial
Hope S. Rugo, MD, discusses the Phase III evERA Breast Cancer trial at SABCS 2025, revealing clinically meaningful improvements with giredestrant plus everolimus for ER-positive, HER2-negative…

Thorsten Kühn MD PhD; SABCS 2025: No Need for Axillary Node Dissection When Clinically Node-Positive Breast Cancers Convert to Node-Negative After Neoadjuvant Chemotherapy
Thorsten Kühn MD PhD discusses findings from the AXSANA/EUBREAST 3(R) study at SABCS 2025. The research indicates that breast cancer patients who convert from clinically node-positive to…

Erika Hamilton MD; 2025 SABCS: Small Molecule HER2 Inhibitor Tucatinib Improves Progression Free Survival in Patients with HER2-positive Metastatic Breast Cancer: in HER2CLIMB-05 Trial
This episode features an interview with Erika Hamilton MD at the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Hamilton discusses findings from the HER2CLIMB-05 trial, showing that adding…

Gaorav Gupta MD PhD; SABCS 2025: Pre-Op Radiation Improved T-cell Infiltration in Hormone Receptor-positive, HER2-negative Invasive Breast Cancer; Could Boost Systemic Therapy Responses
At SABCS 2025, Gaorav Gupta MD PhD presented findings from the TBCRC-053 (P-RAD) study. The research showed that pre-operative radiation therapy significantly increased T-cell infiltration in hormone…

Christian F. Singer MD; 2025 SABCS: Denosumab Bone Protection in ER-Positive Early Breast Cancer Brings Added Benefit with Progesterone Receptor Positive Tumors: ABCSG 18 Study Findings
Dr. Christian F. Singer discusses findings from the ABCSG 18 Study at the 2025 San Antonio Breast Cancer Symposium. The research indicates that post-menopausal women with ER-positive early breast…

Alexis Ann LeVee MD; 2025 SABCS: Pre-Operative Gut Microbiome Predicts Complete Response to Immune Checkpoint Inhibition in Patients with Early-stage HER2-positive Breast Cancer
Alexis Ann LeVee MD presented novel research at the 2025 San Antonio Breast Cancer Symposium. Her team's study, the randomized phase II neoHIP trial, revealed that pre-operative gut microbiome…

Safna Naozer Virji MBBS FPBS; 2025 SABCS: Oncoplastic Breast Cancer Surgery Study Reports High Efficacy with Superior Psychosocial Outcomes in a Low or Middle Income Country Setting
Safna Naozer Virji MBBS FPBS was interviewed at the 2025 San Antonio Breast Cancer Symposium regarding her study on oncoplastic breast cancer surgery. Her research from Pakistan reported high…

Matteo Lambertini MD PhD; San Antonio Breast Cancer Symposium: ALTTO Trial Shows Adjuvant Aromatase Inhibitors Outperform Tamoxifen in Patients with ER-Positive, HER2-Positive Early Breast Cancer
Matteo Lambertini MD PhD discusses new findings from the ALTTO trial at the 2025 San Antonio Breast Cancer Symposium. The long-term analysis reveals that adjuvant aromatase inhibitors lead to…

Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer

Adding Anthracycline Improved Outcomes for Patients with High-Risk HR-positive, HER2-negative Breast Cancer
SAN ANTONIO, USA—Women with hormone receptor positive HER-2 negative breast cancer and Oncotype DX recurrence scores above 31 could benefit from having anthracycline therapy added to their taxane-base

Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer
Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer The important question of whether to recommend risk-reducing surge

E. Shelley Hwang MD MPH: Randomized Study Found Surgery-Sparing Active Monitoring Safe in Patients With Low-risk DCIS
SAN ANTONIO, USA—In patients with hormone receptor-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS) active monitoring, compared with surgery, resulted in no difference in terms of can

AUDIO JOURNAL OF ONCOLOGY: Safe to Spare Post-Mastectomy Chest Wall Radiotherapy in Most Patients with Intermediate Risk Breast Cancer
SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium fr

Younger than 35 with breast cancer: always consider neoadjuvant chemotherapy
SAN ANTONIO, TEXAS—Women with breast cancer under the age of 35 respond very well to neo-adjuvant chemotherapy as the first line of attack against their disease, according to research from the German

Local or regional breast cancer recurrences mandate adjuvant chemotherapy
SAN ANTONIO, TEXAS—Patients with local or regional recurrences of breast cancer, should be treated with chemotherapy as well as surgery and

Breast cancer: less radiotherapy in fewer hospital visits is just as good for preventing relapse
SAN ANTONIO, TEXAS—Three weeks of radiotherapy rather than five — and lower overall doses of radiation — were just has as effective for treating breast cancer in the UK START trial conducted among 445

Audio Journal of Oncology in Advance – January 1st, 2007 – Reporting from San Antonio Breast Cancer Symposium, December 14-17, 2006
Dennis Slamon George Peoples James Holland Massimo Christofanilli Trastuzumab: Mature Results in Early Breast Cancer Show Superiority REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 52

Audio Journal of Oncology 14.1, February 2006
Reporting from: San Antonio Breast Cancer Symposium 2005 Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of Oncology, Milan Pat Price, Christ

Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)
Dennis Slamon, UCLA School of Medicine, Los Angeles It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with carboplatin in HER-2 positive patients with early breast c